Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).
Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S. Rej RK, et al. Among authors: mceachern d. J Med Chem. 2024 Dec 12;67(23):20933-20965. doi: 10.1021/acs.jmedchem.4c01401. Epub 2024 Nov 25. J Med Chem. 2024. PMID: 39585895
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.
Xu R, Zhou H, Bai L, McEachern D, Wu D, Acharyya RK, Wang M, Tošović J, Yang CY, Chinnaswamy K, Meagher JL, Stuckey JA, Liu C, Wang M, Wen B, Sun D, Wang S. Xu R, et al. Among authors: mceachern d. J Med Chem. 2024 Nov 28;67(22):20495-20513. doi: 10.1021/acs.jmedchem.4c01946. Epub 2024 Nov 7. J Med Chem. 2024. PMID: 39509603
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.
Acharyya RK, Rej RK, Hu B, Chen Z, Wu D, Lu J, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Tošović J, Gersch CL, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Sarkari F, Wen B, Sun D, Rae JM, Wang S. Acharyya RK, et al. Among authors: mceachern d. J Med Chem. 2024 Nov 14;67(21):19010-19037. doi: 10.1021/acs.jmedchem.4c01521. Epub 2024 Nov 1. J Med Chem. 2024. PMID: 39485242
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.
Kaneshige A, Yang Y, Bai L, Wang M, Xu R, Mallik L, Chinnaswamy K, Metwally H, Wang Y, McEachern D, Tošović J, Yang CY, Kirchhoff PD, Meagher JL, Stuckey JA, Wang S. Kaneshige A, et al. Among authors: mceachern d. J Med Chem. 2024 Sep 23. doi: 10.1021/acs.jmedchem.4c01009. Online ahead of print. J Med Chem. 2024. PMID: 39311434
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, Wang Y, Bai L, McEachern D, Luo J, Wang M, Li Q, Matvekas A, Wen B, Sun D, Chinnaiyan AM, Wang S. Chen Z, et al. Among authors: mceachern d. J Med Chem. 2024 Apr 11;67(7):5351-5372. doi: 10.1021/acs.jmedchem.3c01789. Epub 2024 Mar 26. J Med Chem. 2024. PMID: 38530938
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D, Lu J, Bai L, Yang CY, Kirchhoff PD, Takyi-Williams J, Wang L, Wen B, Sun D, Ator M, Mckean R, Chinnaiyan AM, Wang S. Xiang W, et al. Among authors: mceachern d. J Med Chem. 2023 Sep 28;66(18):13280-13303. doi: 10.1021/acs.jmedchem.3c01264. Epub 2023 Sep 8. J Med Chem. 2023. PMID: 37683104
120 results